Trial Profile
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Darvadstrocel (Primary)
- Indications Fistula; Rectal fistula
- Focus Registrational; Therapeutic Use
- Acronyms ADMIRE-CD II
- Sponsors TiGenix
- 17 Oct 2023 According to a Takeda (Tigenix ) media release,Full results of the study will be presented at a future medical meeting or published in a peer-reviewed journal.
- 17 Oct 2023 Results presented in the Takeda Media Release.
- 17 Oct 2023 According to a Takeda (Tigenix ) media release,Primary endpoint of Percentage of Participants with Combined Remission at Week 24 has not been met.